| Literature DB >> 23371019 |
Meiyun Fan1, Susan R Pfeffer, Henry T Lynch, Pamela Cassidy, Sancy Leachman, Lawrence M Pfeffer, Levy Kopelovich.
Abstract
Familial melanoma (FM) is a dominantly heritable cancer that is associated with mutations in the tumor suppressor CDKN2A/p16. In FM, a single inherited "hit" occurs in every somatic cell, enabling interrogation of cultured normal skin fibroblasts (SFs) from FM gene carriers as surrogates for the cell of tumor origin, namely the melanocyte. We compared the gene expression profile of SFs from FM individuals with two distinct CDKN2A/p16 mutations (V126D-p16 and R87P-p16) with the gene expression profile of SFs from age-matched individuals without p16 mutations and with no family history of melanoma. We show an altered transcriptome signature in normal SFs bearing a single-hit inherited mutation in the CDKN2A/p16 gene, wherein some of these abnormal alterations recapitulate changes observed in the corresponding cancer. Significantly, the extent of the alterations is mutation-site specific with the R87P-p16 mutation being more disruptive than the V126D-p16 mutation. We also examined changes in gene expression after exposure to ultraviolet (UV) radiation to define potential early biomarkers triggered by sun exposure. UV treatment of SFs from FM families induces distinct alterations in genes related to cell cycle regulation and DNA damage responses that are also reported to be dysregulated in melanoma. Importantly, these changes were diametrically opposed to UV-induced changes in SF from normal controls. We posit that changes identified in the transcriptome of SF from FM mutation carriers represent early events critical for melanoma development. As such, they may serve as specific biomarkers of increased risk as well as molecular targets for personalized prevention strategies in high-risk populations.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23371019 PMCID: PMC3702213 DOI: 10.18632/oncotarget.786
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Normal and familial melanoma individuals included in this study
| Patient | Gender | Age | CDKN2A/p16 mutation |
|---|---|---|---|
| N1 | Male | 51 | None |
| N2 | Male | 51 | None |
| F1 | Male | 18 | V126D |
| F2 | Male | 52 | V126D |
| F3 | Male | 45 | V126D |
| F4 | Female | 36 | R87P |
| F5 | Female | 73 | R87P |
| F6 | Female | 62 | R87P |
| N, normal individual who has no family history of melanoma F, familial melanoma mutation carrier | |||
Figure 1Hierarchical clustering and principal component analysis of gene expression data from SF cultures
Unsupervised hierarchical clustering (upper panel) and principal component analysis (lower panel) were performed on replicate cultures representing normal individuals with wild-type CDKN2A (N) or FM individuals with CDKN2A mutations (F) using normalized expression data of all probes.
Figure 2Differentially-expressed genes in familial SFs with distinct CDKN2A mutations
The inserted tables in the Venn Diagrams list the genes coordinately upregulated (left panel) or downregulated (right panel) in both Group 2 and Group 3 SFs in comparison to normal SFs (Group1).
Figure 3Signaling networks affected by the V126D-p16 mutation
Networks of differentially-expressed genes at baseline in familial SFs with the V126D-p16 mutation (Group 2) were generated using Ingenuity Pathway Analysis software. Genes upregulated or downregulated in Group 2 (vs. Group 1) were highlighted in red or green, respectively.
Figure 4Signaling networks affected by the R87P-p16 mutation
Networks of differentially-expressed genes altered at baseline in familial SFs with a R87P-p16 mutation (Group 3) were generated using Ingenuity Pathway Analysis software. Genes upregulated or downregulated in Group 3 (vs. Group 1) were highlighted in red or green, respectively.
Figure 5Induction of DNA damage by UV irradiation in SF cultures
SFs from a familial individual (F4) and a normal control individual (N1) were UV-irradiated for 20, 40 or 60 seconds, and then fixed in 3.7% formaldehyde at 2 hr after UV exposure. Double-stranded DNA breaks were visualized by γH2Ax immunofluorescence and nuclei were counterstained with DAPI.
Figure 6Hierarchical clustering and principal component analysis of gene expression data from SF cultures before and after UV irradiation
Unsupervised hierarchical clustering (upper panel) and principal component analysis (lower panel) were performed on gene expression data from un-irradiated and UV-irradiated SF cultures from the three cohorts using normalized expression data of all probes.
Figure 7UV-affected genes in normal SFs and familial SFs with distinct CDKN2A mutations
Panel A. Venn diagrams of the UV-affected genes in normal SFs (Group 1) and familial SFs with a V126D-p16 mutation (Group 2). Four genes were coordinately regulated by UV irradiation (3 downregulated and 1 upregulated) in the two groups of SF cultures. Panel B. Venn diagrams of the UV-affected genes in normal SFs (Group 1) and familial SFs with a R87P-p16 mutation (Group 3). Five genes were oppositely regulated by UV irradiation in these two groups of SF cultures.
Enriched Ingenuity Function Groups and Signaling Pathways of UV-regulated genes
| Enriched Ingenuity Function Groups (Group1-UV vs nonUV) | ||||
|---|---|---|---|---|
| Functions Annotation | p-Value | Molecules | # Molecules | |
| cancer | 1.69E-02 | ADRA1B, AMPH, BTG1, CFB, CGB, CHRNB1, CLEC11A, CLEC3B, COLEC12, CSMD1, DAPK1, DUSP1, ECE2, F8, FCGR2A, FUCA1, GLI2, IFI27, IFT57, IGF2BP3, KCNJ8, KIT, KRT7, LGR4, LMO2, MASP1, MLPH, NDRG1, NPTX1, NR3C1, PHGDH, PRRX1, RASSF4, RGS4, ROBO1, RUNDC3B, SATB1, SEL1L, SEMA3C, SERPING1, SOCS2, STON1, TFAP2A, TGFBR3, TM4SF1, ZFPM2 | 46 | |
| metastasis | 2.78E-02 | COLEC12, LGR4, MLPH, PRRX1, RGS4, TGFBR3, TM4SF1 | 7 | |
| Enriched Ingenuity Function Groups (Group2-UV vs nonUV) | ||||
| Functions Annotation | p-Value | Molecules | # Molecules | |
| proliferation of tumor cell lines | 3.87E-02 | ATF3, BAK1, CARD10, CDK11A/CDK11B, FLT3LG, PTMA | 6 | |
| cell cycle progression | 9.05E-03 | ATF3, CARD10, FLT3LG, IL12A, PTMA | 5 | |
| Enriched Ingenuity Function Groups (Group3-UV vs nonUV) | ||||
| Functions Annotation | p-Value | Activation z-score | Molecules | # Molecules |
| metastasis | 1.31E-04 | ANGPTL2, C10orf116, DLGAP5, EPHA2, IGFBP5, MME, MMP3, PAPPA, RGS4, SEL1L3, TM4SF1, TXNIP, VEGFA | 13 | |
| tumorigenesis | 1.37E-08 | 0.832 | ADAMTS5, AFP, ANGPTL2, APOD, ASF1B, AURKA, BARD1, BIRC5, BUB1, C10orf116, CACNA1C, CASD1, CCNB1, CCNB2, CDC20, CDCA8, CDKN3, CENPA, CKS1B, COL7A1, CRIP1, DEPDC1, DLGAP5, DUSP2, ENPP1, EPHA2, EXO1, FAM83D, FBLN5, FUBP1, GBP2, GTF2I, HMMR, HSPB7, IGFBP5, ISOC1, ITGB3, KIF11, KIF14, KIF23, KIF2C, MASP1, MCM10, MCM5, MME, MMP12, MMP3, MXI1, NEK2, OSR2, PAPPA, PAQR4, PDE5A, PDPN, PHLDA2, PIM1, PLK1, PLK4, PLXNC1, PRDM1, PRSS12, PTGER2, RACGAP1, RGS2, RGS4, RNASEH2A, RREB1, SCG2, SCP2, SEL1L3, SFRP1, SLC47A1, SMOX, TM4SF1, TTK, TXNIP, UBE2T, VEGFA, VHL, VRK1, VWA5A, WISP2 | 82 |
| angiogenesis | 6.48E-03 | -0.595 | ANGPTL2, GTF2I, ITGB3, MMP12, RGS4, RHOJ, SCG2, VEGFA | 8 |
| Cell Cycle, arrest in G2 phase | 8.56E-03 | AURKA, CCNB1, IGFBP5, MXI1, PLK1 | 5 | |
| Cell Cycle, arrest in M phase | 3.41E-03 | CDC20, NUF2, PLK1 | 3 | |
| Cell Cycle, arrest in mitosis | 7.82E-04 | BIRC5, BUB1, PLK1, TTK | 4 | |
| Cell Cycle, cell cycle progression | 6.91E-08 | -2.71 | AURKA, BIRC5, BORA, BUB1, CCNB1, CDC20, CDCA8, CDKN3, CENPA, DLGAP5, IGFBP5, KIF11, KIF2C, MXI1, NDC80, NEK2, NUDT1, NUF2, PIM1, PLK1, SKA1, SKA3, TM4SF1, TTK, VEGFA, VHL | 26 |
| Cell Cycle, checkpoint control | 1.52E-02 | BUB1, CDC20, NDC80 | 3 | |
| Cell Cycle, cleavage of cells | 1.89E-02 | BIRC5, FUBP1, SKA1 | 3 | |
| Cell Cycle, cytokinesis | 1.40E-07 | 2.157 | AURKA, BIRC5, CCNB1, CDC20, KIF14, KIF23, PIM1, PLK1, RACGAP1, TM4SF1 | 10 |
| Cell Cycle, delay in initiation of M phase | 1.96E-05 | -0.152 | BIRC5, CCNB1, PIM1, PLK1 | 4 |
| Cell Cycle, G2/M phase | 3.34E-03 | AURKA, BIRC5, CCNB1, IGFBP5, MXI1, PLK1 | 6 | |
| Cell Cycle, interphase | 2.66E-02 | AURKA, BIRC5, CCNB1, CDKN3, IGFBP5, MCM10, MXI1, PIM1, PLK1, TXNIP, VHL | 11 | |
| Cell Cycle, M phase | 6.50E-11 | 1.803 | AURKA, BIRC5, CCNB1, CDC20, CDCA8, DLGAP5, KIF14, KIF23, LRRC6, NUF2, PIM1, PLK1, RACGAP1, SKA1, TM4SF1 | 15 |
| Cell Cycle, mitosis | 5.16E-11 | -1.769 | AURKA, BIRC5, BORA, BUB1, CCNB1, CDC20, CDCA8, CENPA, DLGAP5, IGFBP5, KIF11, KIF2C, NDC80, NEK2, NUF2, PLK1, SKA1, SKA3, TTK, VEGFA | 20 |
| Cell Cycle, senescence of cells | 4.08E-03 | -1.467 | BUB1, CENPA, NUDT1, TM4SF1, VEGFA | 5 |
| Cell Cycle, spindle checkpoint of cells | 1.33E-06 | BIRC5, BUB1, DLGAP5, PLK1, TTK | 5 | |
| cell death | 1.98E-02 | -0.295 | AFP, AURKA, BARD1, BIRC5, CCNB1, CDC20, DEPDC1, EPHA2, FUBP1, HMMR, IGFBP5, IL17D, ITGB3, ITGB3BP, KIF11, KIF14, MCM10, MME, NDC80, NDP, NEK2, NFKBIZ, NUAK2, NUF2, PHLDA2, PIM1, PLK1, PRDM1, PTPN13, RGS4, RIPK3, SCG2, SFRP1, SLC47A1, SMOX, TTK, VEGFA, VHL | 38 |
| differentiation of cells | 5.88E-03 | -0.678 | ANGPTL2, BHLHE41, ENPP1, IGFBP5, IL17D, ITGB3, PDE5A, PRDM1, PRKX, RACGAP1, RGS4, SFRP1, TXNIP, VEGFA, VHL | 15 |
| proliferation of cells | 5.81E-05 | 1.245 | AFF1, AFP, APOD, AURKA, BARD1, BIRC5, BUB1, CDCA8, CDKN3, CKS1B, CRIP1, DLGAP5, ENPP1, EPHA2, ERBB2IP, FABP3, HMMR, IGFBP5, ITGB3, KCNN4, KIF11, KIF2C, LEPREL1, MCM5, MMP12, MXI1, NDP, NEK2, NFATC4, NUDT1, PDE5A, PENK, PHLDA2, PIM1, PLK1, PRDM1, PTGER2, PTPN13, RACGAP1, RGS4, SCG2, SFRP1, SMOX, STEAP2, TTK, TXNIP, UTP20, VEGFA, VHL, WISP2 | 50 |
| invasion of cells | 7.58E-03 | -0.187 | AURKA, EPHA2, FBLN5, HMMR, ITGB3, MMP3, NUAK2, PAPPA, PTGER2, RGS4, SFRP1, VEGFA, VHL | 13 |
| DNA damage | 9.86E-03 | -1.922 | BIRC5, MCM10, PLK1, SMOX | 4 |
| Enriched Ingenuity Canonical pathways (Group3-UV vs nonUV) | ||||
| Ingenuity Canonical Pathways | -log(p-value) | Ratio | Molecules | |
| Mitotic Roles of Polo-Like Kinase | 5.22E+00 | 1.09E-01 | KIF23, PLK4, CDC20, CCNB2, PLK1, KIF11, CCNB1 | |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 2.86E+00 | 8.33E-02 | CKS1B, CCNB2, PLK1, CCNB1 | |
| HIF1A Signaling | 1.57E+00 | 3.92E-02 | VEGFA, MMP3, MMP12, VHL | |
| cAMP-mediated signaling | 1.48E+00 | 2.82E-02 | RGS2, NPR3, ADCY4, RGS4, PDE5A, PTGER2 | |
| Enriched Ingenuity Function Groups (Overlap_Group3-UV vs nonUV and Melanoma vs normal skin) | ||||
| Functions Annotation | p-Value | Activation z-score | Molecules | # Molecules |
| proliferation of cells | 8.79E-04 | 1.247 | AFF1, APOD, AURKA, BIRC5, BUB1, CDKN3, DLGAP5, ENPP1, HMMR, KIF2C, PHLDA2, PIM1, PLK1, PTPN13, SCG2, TTK, TXNIP | 17 |
| cell death | 2.04E-04 | -1.034 | AURKA, BIRC5, CCNB1, CDC20, DEPDC1, HMMR, IL17D, KIF14, NDC80, NUF2, PHLDA2, PIM1, PLK1, PTPN13, SCG2, TTK | 16 |
| cell cycle progression | 6.97E-08 | -1.916 | AURKA, BIRC5, BUB1, CCNB1, CDC20, CDKN3, DLGAP5, KIF2C, NDC80, NUF2, PIM1, PLK1, TTK | 13 |
| Enriched Ingenuity Canonical Groups (Overlap_Group3-UV vs nonUV and Melanoma vs normal skin) | ||||
| Ingenuity Canonical Pathways | -log(p-value) | Ratio | Molecules | |
| Mitotic Roles of Polo-Like Kinase | 4.57E+00 | 6.25E-02 | CDC20, CCNB2, PLK1, CCNB1 | |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 3.56E+00 | 6.25E-02 | CCNB2, PLK1, CCNB1 | |
Figure 8Signaling network of genes affected by UV in familial SFs with a V126D-p16 mutation
The gene network was generated using Ingenuity Pathway Analysis software. Genes upregulated or downregulated by UV in Group 2 were highlighted in red or green, respectively.
Figure 9Signaling networks affected by UV in familial SFs with a R87P-p16 mutation
The gene networks were generated using Ingenuity Pathway Analysis software. Genes upregulated or downregulated by UV in Group 3 were highlighted in red or green, respectively.
Figure 10Expression in normal skin and melanoma tissue of genes affected by UV in familial SFs with a R87P-p16 mutation
RNA was isolated from (Panel A) unirradiated and UV-irradiated SFs from Group 1 (normal) and Group 3 (a R87P-p16 mutation), or (Panel B) normal skin and melanoma tissue, and mRNA levels of the indicated genes were measured by qPCR, normalized to β-actin expression, and presented as means. The horizontal line shows the mean value for all members of each group of samples.